Pulled from Benzinga Pro data, Phibro Animal Health (NASDAQ: PAHC ) showed a loss in earnings since Q3, totaling $7.49 million. Sales, on the other hand, increased by 6.55% to $255.30 million during Q4. Phibro Animal Health reached earnings of $17.69 million and sales of $239.60 million in Q3. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of … Full story available on Benzinga.com
→ Google 번역
Phibro Animal Health Corporation (NASDAQ:NASDAQ:PAHC) Q4 2022 Earnings Conference Call August 25, 2022 09:00 A.M. ET Company Participants Damian Finio - CFO Jack C.
→ Google 번역
Phibro Animal Health Corp (NASDAQ: PAHC ) posted Q4 FY22 sales of $255.3 million , +16% Y/Y, beating the consensus of $246.02 million. Adjusted EPS increased 13% to $0.36, missing the consensus of $0.38. The gross margin decreased 100 basis points to 30.7%. The adjusted EBITDA … Full story available on Benzinga.com
→ Google 번역
Phibro Animal Health (NASDAQ: PAHC ) is set to give its latest quarterly earnings report on Wednesday, 2022-08-24. Here''s what investors need to know before the announcement. Analysts estimate that Phibro Animal Health will report an earnings per share (EPS) of $0.38. Phibro Animal Health bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, … Full story available on Benzinga.com
→ Google 번역
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq:PAHC) expects to announce its fourth quarter and fiscal year 2022 financial results on Wednesday, August 24, 2022, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 25, 2022, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be availabl
→ Google 번역
Phibro Animal Health (PAHC) and Rejuvenate Bio on Wednesday announced a development and commercialization collaboration for a gene therapy to treat mitral valve disease ((MVD)) in…
→ Google 번역
Major players in the poultry healthcare market are Ceva, Zoetis, Venkys India, Phibro Animal Health Corporation, Merk and Co Inc. , Boehringer Ingelheim, Hester Biosciences Limited, ROMVAC COMPANY S. A. Major players in the poultry healthcare market are Ceva, Zoetis, Venkys India, Phibro Animal Health Corporation, Merk and Co Inc. , Boehringer Ingelheim, Hester Biosciences Limited, ROMVAC COMPANY S. A.
→ Google 번역
Das Instrument PB8 US71742Q1067 PHIBRO ANIMAL HEALTH A EQUITY wird ex Dividende/Zinsen gehandelt am 31.05.2022 The instrument PB8 US71742Q1067 PHIBRO ANIMAL HEALTH A EQUITY has its ex-dividend/interest day on 31.05.202202. [ mehr ]
→ Google 번역
Major players in the nutritional feed additives market are BASF SE, Cargill, Archer Daniels Midland Company, Evonik Industries AG, Nutreco N. V. , Kemin Industries Inc. , Adisseo, Alltech, Phibro Animal Health Corporation. Major players in the nutritional feed additives market are BASF SE, Cargill, Archer Daniels Midland Company, Evonik Industries AG, Nutreco N. V. , Kemin Industries Inc. , Adisseo, Alltech, Phibro Animal Health Corporation.
→ Google 번역
This report studies the Poultry Drugs Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Poultry Drugs market segmented by company, region, type []
→ Google 번역
On May 3, 2021, Phibro Animal Health (NASDAQ:PAHC) announc
→ Google 번역
Phibro Animal Health Corp. - Class A (PAHC) shares closed today at 0.9% below its 52 week high of $27.76, giving the company a market cap of $559M. The stock is currently up 42.5% year-to-date, up 23.3% over the past 12 months, and up 61.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.3%. Trading Activity Trading volume this week was 2.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 2.8% higher than its 5-day moving average, 7.6% higher than its 20-day moving average, and 16.8% higher than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 100.3% The company's stock price performance over the past 12 months lags the peer average by -64.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -140.3% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
NEW YORK, NY / ACCESSWIRE / February 4, 2021 / Phibro Animal Health Corp. (NASDAQ:PAHC) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on February 4, 2021 at 9:00 AM Eastern Time.
→ Google 번역
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health will represent and market Virbac’s newly approved TULISSIN® 100 brand of tulathromycin.
→ Google 번역
Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Global Animal Treatment Market, By Animal Type (Dogs, Cats, Cattle, Pigs, Horses, Poultry), Treatment (No Medicalization, Basic Medicalization, Veterinary Care), Country (U.S., Canada, Mexico, Germany, Italy,
→ Google 번역
Market Insights Global anti-coccidial drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets
→ Google 번역
The animal healthcare is a rapidly growing market which has full filled the needs of several livestock and companion animal species. Currently, various established companies are increasingly focusing on the development of healthcare products and services for companion animals. The
→ Google 번역
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
→ Google 번역
TEANECK, N.J.--(BUSINESS WIRE)--Nutritional specialty product helps dairy cows be healthy and stay healthy. Phibro Animal Health Corporation introduces Omnigen Pro.
→ Google 번역
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its second quarter financial results on Monday, February 3, 2020, after the market closes. Phibro management will host a conference call and webcast on Tuesday, February 4, 2020 at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (866) 21
→ Google 번역
Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.
→ Google 번역
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (NASDAQ:PAHC) today announced its financial results for its first quarter ended September 30, 2019. Highlights for the September 2019 quarter (compared to the September 2018 quarter) Net sales of $190 million, a decrease of $10 million, or 5% Net income of $3 million, a decrease of $14 million, or 85% Diluted EPS of $0.06, a decrease of $0.34, or 85% Adjusted EBITDA of $20 million, a decrease of $10 million, or 35% Adjusted dilute
→ Google 번역
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Credit Suisse Healthcare Conference being held at the Phoenician Resort in Scottsdale, Arizona. Chief Financial Officer Richard Johnson will address financial analysts and investors on Tuesday, November 12, 2019 at 5:00 PM Mountain Time. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.
→ Google 번역
Phibro Animal Health Corporation (NASDAQ:PAHC) Q3 2019 Earnings Conference Call May 7, 2019 9:00 AM ET Company Participants Richard Johnson – Chief Financial Of
→ Google 번역